Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jan;7(1):1-6.
doi: 10.1593/neo.04373.

Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma

Michael I Koukourakis  1 , Alexandra Giatromanolaki, Efthimios Sivridis, Kevin C Gatter, Adrian L Harris; Tumor and Angiogenesis Research Group
Affiliations

Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma

Michael I Koukourakis et al. Neoplasia. 2005 Jan.

Abstract

Pyruvate dehydrogenase (PDH) catalyzes the conversion of pyruvate to acetyl-coenzyme A, which enters into the Krebs cycle, providing adenosine triphosphate (ATP) to the cell. PDH activity is under the control of pyruvate dehydrogenase kinases (PDKs). Under hypoxic conditions, conversion of pyruvate to lactate occurs, a reaction catalyzed by lactate dehydrogenase 5 (LDH5). In cancer cells, however pyruvate is transformed to lactate occurs, regardless of the presence of oxygen (aerobic glycolysis/Warburg effect). Although, hypoxic intratumoral conditions account for HIF1alpha stabilization and induction of anaerobic metabolism, recent data suggest that high pyruvate concentrations also result in HIF1alpha stabilization independently of hypoxia. In the present immunohistochemical study, we provide evidence that the PDH/PDK pathway is repressed in 73% of non small cell lung carcinomas, which may be a key reason for HIF1alpha stabilization and "aerobic glycolysis." However, about half of PDH-HIF pathway, and patients harboring these tumors have an excellent postoperative outcome. A small subgroup of clinically aggressive tumors maintains a coherent PDH and HIF/LDH5 expression. In contrast to cancer cells, fibroblasts in the tumor supporting stroma exhibit an intense PDH but reduced PDK1 expression favoring maximum PDH activity. This means that stroma may use lactic acid produced by tumor cells, preventing the creation of an intolerable intratumoral acidic environment at the same time.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression patterns of PDH and PDK in normal lung and lung cancer. (a) Strong cytoplasmic expression of PDH in normal bronchi (thick arrows) and adjacent stroma fibroblasts (thin arrows). (b) Intense PDH expression in the alveolar tissue (thick arrows). (c) Lack of PDH expression in a squamous cell lung carcinoma (thin arrows) adjacent to PDH-positive alveolar tissue (thick arrows). (d) Focal PDH expression in cancer cells (black arrows). (e) Lack of PDH expression in squamous cell lung cancer (thin arrows) in a background of tumor-supporting stroma exhibiting a strong PDH reactivity (thick arrows). Strong expression of PDK in cancer cells (thin arrows) of a squamous cell carcinoma (f) and adenocarcinoma (g). Note the repression of PDK in the tumor-supporting stroma (thick arrows).
Figure 2
Figure 2
Kaplan-Meier overall survival curves according to PDH expression, stratified for HIF1α (a) and LDH5 expression (b) (n = 42). Note that cases with contemporaneous defective metabolism in both aerobic (low PDH expression) and anaerobic (low HIF1α or low LDH5) directions had a particularly favorable outcome.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Harris RA, Bowker-Kinley MM, Hyang B, Wu P. Regulation of the activity of the pyruvate dehydrogenase complex. Adv Enzyme Regul. 2002;42:2249–2259. - PubMed
    1. Reed LJ, Hackert ML. Structure-function relationships in dihydrolipoamide acyltransferases. J Biol Chem. 1990;265:8971–8974. - PubMed
    1. Sanderson SJ, Miller C, Lindsay JG. Stoichiometry, organisation and catalytic function of protein X of the pyruvate dehydrogenase complex from bovine heart. Eur J Biochem. 1996;236:68–77. - PubMed
    1. Maeng CY, Yazdi MA, Niu XD, Lee HY, Reed LJ. Expression, purification, and characterization of the dihydrolipoamide dehydrogenase-binding protein of the pyruvate dehydrogenase complex from Saccharomyces cerevisiae. Biochemistry. 1994;33:13801–13807. - PubMed
    1. Harris RA, Bowker-Kinley MM, Wu P, Jeng J, Popov KM. Dihydrolipoamide dehydrogenase-binding protein of the human pyruvate dehydrogenase complex. DNA-derived amino acid sequence, expression, and reconstitution of the pyruvate dehydrogenase complex. J Biol Chem. 1997;272:19746–19751. - PubMed

Publication types

MeSH terms

Substances